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Genetic and Environmental Factors
Affecting Host Response to Drugs
and Other Chemical Compounds
in Our Environment
by Elliot S. Vesell* and G. Thomas Passananti*
Compared to laboratory animals, humans are extremely heterogeneous with respect to the many
factors that can influence the distribution and biological effects oftoxic chemicals. This heterogeneity can
prevent an accurate assessment of the impact of a particular toxic compound on the health of an indi-
vidual subject. Some ofthe factors that can significantly modify the host response to certain drugs, which
serve in this review as a model for environmental chemicals, are enumerated and discussed. Although the
mechanisms by which many ofthese factors modify the biological effects ofcertain environmental chemi-
cals and drugs have been determined in some cases, better definition ofthe nature ofinteractions between
these factors and environmental chemicals in a particular individual is required at a biochemical and
molecular level. Recommendations are offered for the further development ofour knowledge concerning
interactions between environmental chemicals and such factors in a particular individual.
This background document considers certain as-
pects of the impact of environmental chemicals on
the development of disease and injury in man. The
primary focus is the role played by certain key vari-
ables in determining how humans respond to en-
vironmental chemicals and drugs. Since few exper-
iments have been performed, for obvious ethical
reasons, on the biological effects of exposing
human populations to clearly established toxic
chemicals, we are unaware at the present time of
the precise way in which host variations, diet, ge-
netic constitution, or prior disease states influence
the degree and type oftoxicity experienced by indi-
viduals exposed to toxic chemicals. Nor has it
proved satisfactory to extrapolate from laboratory
animal data to man because species differences are
great with respect to the disposition of drugs and
toxic chemicals. Hundreds of examples of large
species differences in drug disposition have been
published. Moreover, in many cases estimation of
the dose that different human beings receive as a
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result of chronic exposure to potentially toxic
chemicals in the environment of our modern indus-
trial cities is difficult. Effects and interactions of
various potentially toxic chemicals in the environ-
ment are difficult to assess because both the chemi-
cal nature as well as the concentration of many of
these environmental compounds remain to be de-
fined precisely. For these reasons, various drugs,
administered alone or in combination, will have to
serve temporarily, at least, as models of how other
environmental chemicals might act and interact in
different individuals to produce toxicity and how
certain genetic and environmental factors could
modify their effects in man.
The virtue of using drugs as a model of how po-
tentially toxic chemicals might act in man is that the
chemical nature, the dose, and the route of ad-
ministration of the drug can be clearly defined and
the individual himselfused as acontrol, sothatrela-
tively minor effects ofvarious genetic and environ-
mental factors on drugdisposition can be examined.
However, the utilization of drugs as a model does
not by any means obviate all methodological prob-
lems. The main problem in the use of man as a
subject to define environmental and genetic vari-
October 1977 159ables affecting drug disposition is that man himself
is exceedingly heterogeneous with repect to many
genetic and environmental factors. Each human
being, except for persons who are one of a set of
identical twins or triplets, is unique with respect to
many environmental and genetic factors that could
influence drug disposition. Therefore, most studies
on the role ofthese factors in determining drug dis-
position have had to be performed in experimental
animals where the laboratory conditions with re-
spect to the environment and genetic background of
the animal can be most closely defined and held
investigation, may appearimpressive at firstglance,
the precise quantitative definition ofthe role ofeach
factor in determining drug disposition and the
mechanisms by which each factor operates to alter
drug disposition have not yet been satisfactorily
elucidated in mostcases. Nevertheless, the division
of variables shown in Table 1 into those affecting
the external environment of laboratory animals,
those operating on their internal environment and
those determining the pharmacokinetic and phar-
macodynamic aspects by which a drug is adminis-
tered may prove useful.
Table 1
Variables in the Variables in the Pharmacologic
external environment internal environment variables
Air exchange and composition Adjuvant arthritis Drugs
Barometric pressure Age Acute vs. chronic administration
Cage design-materials Alloxan diabetes Bioavailability
(crowding, exercise) Cardiovascular function Dose, withdrawal
Cedar and other softwood Castration and hormone Presence of other drugs or food
bedding replacement Routes ofadministration
Cleanliness Circadian and seasonal Tolerance
Coprophagia variations Vehicle
Diet (food and water) Dehydration Volume of material injected
Gravity Disease
Hepatic microsomal enzyme hepatic, renal, malignant,
induction or inhibition by endocrine (thyroid, adrenal)
insecticides, piperonyl butoxide, Estrous cycle
heavy metals, detergents, Fever
organic solvents, ammonia, vinyl Gastrointestinal function, patency
chloride, aerosols containing and flora
eucalyptol, etc. Genetic constitution (strain and
Handling species differences)
Humidity Hepatic blood flow
Light cycle Infection
Noise level Malnutrition, starvation
Temperature Pregnancy
Sex
Shock (hemorrhagic or endotoxic)
Stress
constant. Use of laboratory animals to study the
factors that affect drug disposition is fraught with
difficulties because the processes that control drug
disposition (drug absorption, distribution, biotrans-
formation and excretion) are exceedingly sensitive
to perturbation by many diverse conditions (1).
The list shown in Table 1 (1) ofgenetic and en-
vironmental factors affecting drug disposition in
laboratory animals is at best only partial. While this
compilation, accumulated over several decades of
From what we now know of how drugs enter,
pass through, and are eliminated by an organism,
we can categorize certain possible mechanisms by
which chemicals and drugs act and interact to pro-
duce toxicity. Table 2 identifies discrete biochemi-
cal processes and sites responsible for the disposi-
tion ofdrugs introduced into an organism; the vari-
ables in the external and internal environment listed
in Table 1 can act to alter the disposition ofa drug
or toxic chemical in an organism at these sites.
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Absorption of drug from its site of entry
Distribution of drug in the organism
Biotransformation of drug in the organism
Interaction of drug with receptor sites or sites
Interaction of drug with elimination mechanism
Table 2
Example
Tetracyclines and albumin-containing antacids
Thiopental in brain and fat
Warfarin displacement from albumin by various drugs, including
phenylbutazone and flufenamic acid
Acetylation of albumin after chronic aspifin administration, thereby
altering albumin binding of other drugs
Phenobarbital, diphenylhydantoin, ethanol, causing induction of
hepatic MFO
Disulfiram and allopufinol causing inhibiton of hepatic MFO
Ethanol treatment of methanol intoxication
where toxicity occurs in the organism
Ethanol and chlortrimeton, barbituarates, methaqualone, etc.
Nalorphine and morphine
CIOj- and SCN- as inhibitors of iodide transport into the thyroid
Thioamide antithyroid drugs and peroxidase in thyroid cell
H,-receptor antagonists of histamine (diphenhydramine, pyrilamine,
chlorpheniramine, chlorcyclizine, promethiazine)
Phenoxybenzamine or dibenemine occupation ofa-adrenergic recep-
tor
Propranolol occupation of 13 receptor
Acetylcholine and atropine, scopolamine
Cholinergic receptor antagonism by physostigmine, neostigmine, ed-
rophonium, DFP, paraoxon, malathion, ERN, TEPP, OMPA
Acetazolamide and carbonic anhydrase in renal tubular cell
Thiazide diuretic and Na+ and Cl- reabsorption in renal tubule
Dose-dependent effects of benemid and salicylic acid on uric acid
reabsorption and secretion by the renal tubule
Heavy metal and renal tubules
Renal disease and reduced renal elimination of drugs and their
metabolites
Classifying Drug Response:
Susceptible Individuals and
Populations
The same dose of a certain drug given by the
same route to patients of the same age and sex,
suffering from the same disease, may produce toxic-
ity in some, the desired therapeutic effect in others
and no effect whatever in still others. Physicians
have come to recognize that in practice drugs rarely
behave as ideally as they are described in most
pharmacology texts and that drugs frequently do
not exhibit the therapeutic effects hoped for when
they are prescribed. Paul Dudley White estimated
this disappointing result to have occurred in more
than halfhis patients. The basis for the discrepancy
between anticipated and actual responses to drugs
lies in the immense variation among subjects. Thus,
an inquiry seems warranted into the precise nature
of this interindividual variation, which had previ-
ously been ill defined and dismissed with the vague
term "biological variation". The same wide range
ofeffect has been observed in the toxicity ofcertain
chemicals, such as carbon tetrachloride or strych-
nine in laboratory animals (2).
Figure 1 shows three types of curves, each de-
scribing a genetically distinct mode of inherited
variation encountered clinically when the same
dose of a given drug is administered by the same
route to a group of patients or normal volunteers,
and a particular quantitative response to a drug is
measured. This measurement could be the concen-
tration of the drug or of its metabolites in biological
fluids or the change produced by the drug in the
patient's pulse rate, blood pressure, or activity of a
particular enzyme.
The simplest curve describing variation is the
unimodal, Gaussian curve (type A in Fig. 1) (3), but
its single-humped, deceptively simple curve is the
most difficult to interpret. The first interpretation of
the unimodal distribution curve is genetic similarity
of the population tested with respect to the genes
controlling the particular response being measured.
For example, each ofthe subjects investigated may
have the same genetically-determined blood group
or the same activity of a specific drug-metabolizing
enzyme, such as plasma pseudocholinesterase, the
enzyme responsible for biotransformation of suc-
cinylcholine.
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FIGURE 1. Three distinct distribution curves for response to a drug by individuals in a population. See text for an
explanation of the genetic mode of transmission responsible for producing each curve.
At least two alternative interpretations of this
unimodal distribution curve should be considered.
The first of these questions is whether the test em-
ployed was sufficiently sensitive to separate inher-
ently different populations from one another. Ap-
plication of a more sophisticated test might possibly
distinguish further among the subjects by producing
multimodal curves from the unimodal curve. This
situation has actually been found several times in
pharmacogenetics. For example, while plasma
pseudocholinesterase activity (measured in a large
population with the substrate benzoylcholine) pro-
duced a broad unimodal curve, this same popula-
tion studied with the pseudocholinesterase inhibitor
dibucaine, as well as with benzoylcholine, yielded a
trimodal distribution, like that shown as type C in
Figure 1. Furthermore, family studies of atypical
plasma pseudocholinesterase later proved that the
mode of inheritance of this aberrant enzyme cor-
responded to type C, rather than type A. Thus,
distinction between type A and type C is important
because each curve represents a different genetic
mechanism or mode of transmission. Type A, as
previously noted, may arise from a population of
individuals identical with respect to the genes at the
genetic locus controlling the trait being measured,
whereas type C represents expression of a trait in-
herited in an autosomal recessive fashion. Each of
the three peaks in type C corresponds to a different
combination ofgenes at the genetic locus governing
the trait being measured. Autosomal recessive in-
heritance indicates that affected individuals who are
shown in the smallest peak in type C have a double
dose ofa rare mutant gene responsible forlow activ-
ity of a particular enzyme or protein. The middle
peak in type C corresponds to heterozygotes in the
population. They possess one mutant and one nor-
mal gene at the particular genetic locus in question,
and they exhibit concentrations ofthe involved en-
zyme or protein intermediate between those for af-
fected and for normal individuals. The third and
largest peak in type C represents homozygous nor-
mal individuals possessing two normal genes and
thus exhibiting highest activity of the specific en-
zyme or protein controlled by this genetic locus.
Type B represents the characteristic distributionfor
a trait transmitted as a Mendelian autosomal dom-
inant. Unlike autosomal recessive traits, where two
abnormal genes must be present at the genetic locus
to give full expression ofthe trait, traits inherited in
an autosomal dominant fashion require, for full ex-
pression, the presence of only a single abnormal
gene at the particular genetic locus controlling the
trait.
The second alternative explanation for the uni-
modal distribution is that the trait being measured is
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162controlled by genes at multiple loci, rather than the
single genetic locus that gives rise to type B or type
C. Genes at multiple loci play important roles in
regulating such metrical, quantitative traits as stat-
ure, intelligence quotient, blood pressure, and large
variations in elimination rates of certain drugs.
Also, multigenetic effects have been postulated in
certain congenital malformations, such as cleft lip
and palate, pyloric stenosis, and clubfoot, and in
certain common disorders such as peptic ulcer and
diabetes mellitus.
Single Factor Inheritance
A condition inherited as a single factor is con-
trolled by alleles at only one genetic locus; such
pharmacogenetic conditions, which are transmitted
as single factors, are listed in Table 3. As opposed
to inheritance patterns oftraits transmitted as single
factors, in polygenically controlled traits the multi-
ple genes at several discrete loci each make a quan-
tum contribution. Thus, the final expression of a
polygenically controlled trait is the sum ofthe con-
tributions from each ofthese multiple loci. Whereas
distribution curves ofresponse for genetic traits in-
herited as single factors are discontinuous, gener-
ally being either bimodal for dominant traits (type
B) or trimodal for traits transmitted as autosomal
recessives (type C), distribution curves for poly-
genically controlled traits are continuous, illus-
trated in large populations by bellshaped Gaussian
curves for intelligence quotients and blood pressure
(type A).
Several hundred pathological states inherited as
simple single factors have been identified in man
and intensively investigated. Much less attention
has been devoted to genetic analysis of such preva-
lent disorders as cancer, arteriosclerosis and hy-
pertension, which may be to some extent under
polygenic control. Genetic analysis of commonly
occurring polygenically controlled pathological
states is technically more difficult than genetic
analysis of rare conditions transmitted as simple
single factors. This is because rare abnormal genes
segregate simply in several generations and can eas-
ily be traced without the complication of the intro-
duction, through marriage, of similar abnormal
genes. Another reason for the absence ofextensive
genetic analysis of polygenically transmitted disor-
ders is that polygenic control may be expressed
only through complex interactions with etiological
factors of an entirely environmental nature.
The pharmacogenetic conditions listed in Table 3
could be expanded by including several other in-
born errors of metabolism associated with abnor-
mal, toxic responses to exogenously administered
compounds, such as phenylketonuria, galac-
tosemia, Willson's disease, Crigler-Najjar syn-
drome, and Lesch-Nyhan syndrome. Regardless of
where the line ofdemarcation is drawn, recognition
that many hereditary conditions cause dramatic al-
terations in responsiveness to certain drugs has im-
portant implications. Probably many additional, as
yet unidentified, genetic defects result in adverse
reactions to certain drugs, and the role of heredity
in controlling the expression of allergic reactions
due to hypersensitivity to certain drugs remains to
be defined.
Reducing Adverse Reactions
Recently, the scope of pharmacogenetics has
been extended considerably beyond the conditions
listed in Table 3, largely in an attempt to apply
pharmacogenetic principles for analyzing and, it is
hoped, for reducing the increasing number of ad-
verse reactions to commonly prescribed drugs. The
magnitude ofthis problem is indicated by estimates
from several medical centers that one in twenty
hospital admissions results from an adverse reac-
tion to a prescribed drug. This high rate led the
U.S. Task Force on Prescription Drugs to identify
adverse reactions to commonly prescribed drugs as
a major medical problem. The conditions listed in
Table 3, because most are rare and produced toxic-
ity after relatively few drugs, probably do not con-
tribute substantially to the total number of seri-
ous adverse reactions. A notable exception is
glucose-6-phosphate dehydrogenase deficiency,
which afflicts one in ten male blacks in the United
States. Also, slow inactivation ofisoniazid arises in
approximately 50% ofthe United States population.
To avoid the polyneuritis that occurs from pyridox-
ine deficiency, mainly in certain slow acetylators
when isoniazid is given alone, pyridoxine adminis-
tration is recommended with isoniazid. As indi-
cated in the following table, several other drugs,
including several sulfonamides, phenelzine, pro-
cainamide, and hydralazine, are metabolized by the
same enzyme that acetylates isoniazid. Therefore,
slow acetylators of isoniazid also acetylate these
othertherapeutic agents slowly. Patients in whom a
lupus-like syndrome develops during hydralazine
therapy are predominantly slow isoniazid acet-
ylators.
Before the administration ofsuccinylcholine as a
pre-anesthetic agent, typing to detect atypical
serum pseudocholinesterase may prevent adverse
reactions because apnea can develop for long
periods in patients receiving succinylcholine ifthey
possess atypical pseudocholinesterase. As shown
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Name of entity Enzyme missing Drugs
Genetic conditions probably transmitted as single factors altering the way the body acts on drugs (altered drug metabolism)
Acatalasia
Slow inactivation of isoniazid
Suxamethonium sensitivity or
atypical pseudocholinesterase
Diphenylhydantoin toxicity due to
deficient parahydroxylation
Bishydroxycoumarin sensitivity
Acetophenetidin-induced methemo-
globinemia
Catalase in erythrocytes
Isoniazid acetylase in liver
Pseudocholinesterase in plasma
?Mixed function oxidase in microsomes
that parahydroxylate diphenylhydan-
toin
?Mixed function oxidase in liver micro-
somes that hydroxylate bishydroxy-
coumarin
?Mixed function oxidase in liver micro-
somes that deethylate acetophenetidin
Hydrogen peroxide
Isoniazid, sulfamethazine, sulfama-
prine, phenelzine, dapsone, hydral-
azine, procainamide
Suxamethonium or succinylcholine
Diphenylhydantoin
Bishydroxycoumarin
Acetophenetidin
Genetic conditions probably transmitted as single factors altering the way drugs act on the body
Warfarin resistance ?Altered receptor or enzyme in liver Warfarin
with increased affinity for vitamin K
Glucose-6-phosphate dehydrogenase Glucose-6-phosphate dehydrogenase Analgesics
deficiency, favism or drug-induced Acetanilide, acetylsalicylic acid,
hemolytic anemia acetophenetidin (phenacetin), an-
tipyrine, aminopyrine (Pyramidon)
Sulfonamides and sulfones
Sulfanilamide, sulfapyridine,
N2-acetylsulfanilamide, sulfacetamide
sulfisoxazole (Gantrisin), thiazosul-
fone, salicylazosulfapyridine (Azul-
fidine), sulfoxone, sulfamethox-
ypyridazine (Kynex)
Antimalarials
Primaquine, pamaquine, pentaquine,
quinacrine (Atabrine)
Nonsulfonamide antibacterial agents
Furazolidone, nitrofurantoin
(Furadantin), chloramphenicol,
p-aminosalicylic acid
Miscellaneous drugs
Naphthalene, vitamin K, probenecid,
trinitrotoluene, methylene blue, di-
mercaprol (BAL), phenylhydrazine,
quinine, quinidine
Drug-sensitive hemoglobin
Hemoglobin Zurich
Hemoglobin H
Inability to taste phenylthiourea or
phenylthiocarbamide
Glaucoma due to abnormal response of
intraocular pressure to steroids
Malignant hyperthermia with muscular
rigidity
Methemoglobin reductase deficiency
Arginine substitution for histidine at the
63rd position of the 8-chain of hemo
globin
Hemoglobin composed of four ,-chains
Unknown
Unknown
Unknown
Methemoglobin reductase
Sulfonamides
Same drugs as listed above for G-6-PD
deficiency
Drugs containing the N-C=S groups
such as phenylthiourea, methyl and
propylthiouracil
Corticosteroids
Various anesthetics, especially
halothane
Same drugs as listed above for G-6-PD
deficiency
Environmental Health Perspectives 164in Table 3, approximately one person in 2500
has a double dose of the gene for atypical plasma
pseudocholinesterase and hence is susceptible to
the possibility of prolonged apnea after succinyl-
choline administration.
Although most of the other conditions listed in
Table 3 are rare, they have not been extensively
sought and may occur more frequently in certain
populations. A major contribution of phar-
macogenetics is to alert physicians to the possibility
that several unusual drug reactions are inherited
and will thus develop in some relatives of affected
persons after administration of the offending
therapeutic agents. In this connection, half of the
siblings and half of the children of anyone who has
inherited the dominantly-transmitted gene causing
the rare, but frequently fatal, malignant hyperther-
mia with muscular rigidity will also exhibit a similar
aberrant response during anesthesia with the agents
listed in Table 3. Therapy of malignant hyperther-
mia with intravenous procaine or procainamide has
been reported to produce dramatic relief of fever
and rigidity.
Table 3 (3) also reveals an interesting example of
a much looser association between agenetically de-
termined drug response and a particular disease.
Persons unable to taste either phenylthiocarbamide
orpropylthiouracil constitute approximately 30% of
the population. They are at higher risk than "tast-
ers" for development of nodular goiter or multiple
thyroid adenomas. On the other hand, toxic diffuse
goiter occurs more frequently among tasters than
among nontasters. The conditions listed in Table 3
have been divided into those involving defective
drug metabolism and those involving defective in-
teraction of the drug with tissues, thereby produc-
ing abnormal pharmacological responses.
Genetic Variations in
Drug Clearance
A major cause of adverse reactions is drug ac-
cumulation of toxic concentrations in certain per-
sons who, for various reasons, are unable to elimi-
nate normal doses of a therapeutic agent as fast
as most others. Large variations in the rates at
which healthy, nonmedicated volunteers clear
antipyrine (4), bishydroxycoumarin (5), and
phenylbutazone (6)from theirplasma were reported
20 years ago from Brodie's laboratory. More re-
cently, large differences have also been shown
among normal subjects in the plasma concentra-
tions of chlorpromazine, propranolol, warfarin,
phenytoin, or procainamide after a standard dose of
any one of these drugs. Formerly, it was assumed
that if a given drug were administered to a popula-
tion in the same dose and by the same route, all
subjects would have similar blood and receptor site
concentrations of the drug, and hence that all sub-
jects would respond similarly to the therapeutic
agent. In the light of these large individual differ-
ences in rates of elimination of many drugs, the
principle ofwide variations in the disposition ofand
responsiveness to therapeutic agents is now being
proclaimed. This principle of pharmacological indi-
viduality has long been appreciated by practicing
physicians.
Mechanisms of Variation
The mechanism responsible for large individual
variations in plasma half-lives of several commonly
used drugs was recently elucidated by the applica-
tion of an old technique. The twin method, intro-
duced by Sir Francis Galton in 1875, estimates the
relative contribution of environmental and genetic
factors in producing a particular trait. The method,
based on a comparison for any given trait of the
intratwin differences for identical and fraternal
twins, assumes environmental equality. For traits
controlled primarily by environmental factors, in-
tratwin differences should be of similar magnitude
in identical and fraternal twins. However, for traits
controlled primarily by genetic factors, there should
be a difference in the magnitude of intratwin differ-
ences, since identical twins share all their genes,
but fraternal twins have in common, on the average,
only halfoftheir genes. A mathematical expression
for the relative control of a trait by hereditary fac-
tors is given by the following fraction, where V rep-
resents variance and FT and IT refer to fraternal
twins and identical twins, respectively:
(V within pairs of FT) - (V within pairs of IT)
(V within pairs of FT)
This formulagives a range ofvalues from 0, indicat-
ing negligible hereditary and complete environmen-
tal control, to 1, indicating virtually complete
hereditary influence. Appreciable environmental
contributions to individual differences in drug
metabolism were expected in man on the basis of
investigations in laboratory animals. Numerous en-
vironmental factors, such as exposure to inducing
agents, degree of health or illness and hormonal or
nutritional status, are known to alter the rates at
which animals metabolize certain drugs. In mice,
responsiveness to a drug such as hexobarbital dif-
fers according to age, sex, litter, painful stimuli,
ambient temperature, degree of crowding, time of
administration and type of bedding. Such experi-
ments imply that in man a large component in the
causation of individual variations in drug
October 1977 165metabolism would be environmental.
Therefore, the results of genetic studies in man
on phenylbutazone, antipyrine, and bishydroxy-
coumarin were unexpected because they indicated
in healthy, nonmedicated twins almost complete
hereditary and negligible environmental control.
Other twin studies on halothane and nortriptyline
established predominantly genetic control over
large individual differences in the metabolism of
these drugs. Although in healthy, nonmedicated
subjects a genetic influence over large variations in
drug elimination was demonstrated by these twin
studies, investigations of twins fail to define une-
quivocally the mode of inheritance of genetically
controlled variations in drug elimination.
Mode of Inheritance
Distribution curves ofthe twin data do offer clues
to the mode ofinheritance. Forisoniazid excretion in
urine, twin data suggest a multimodal distribution
curve indicating single-factor inheritance, later
firmly established independently by family studies.
In contrast to the curves for isoniazid excretion, the
distribution histograms for antipyrine and nortrip-
tyline are closer to the unimodal, continuous curves
observed in polygenically controlled traits. When
family studies were performed for bishy-
droxycoumarin (7), nortriptyline (8), and phenyl-
butazone (9), the results were in substantial agree-
ment with this genetic hypothesis. The family
studies revealed a significant regression of mean
offspring value on midparent value, a result consis-
tent with polygenic control. Nevertheless, before
polygenic inheritance can be firmly established as
the genetic mechanism for controlling interindivid-
ual variations in the basal rates of elimination of
these drugs either on the basis of twin or family
studies, it would be important to measure rates of
production of the major metabolites of each drug,
rather than simply the disappearance rate of the
parent compound. Since hepatic metabolism of
each drug is complex, probably involving several
distinct reactions controlled by different proteins,
the investigator can obtain a more direct estimate of
the function of the gene controlling one particular
protein by measuring the rate ofproduction ofeach
metabolite independently of the others. On the
other hand, measuring the disappearance of a par-
entdrug represents a more dilutedapproximation of .
gene function because such values combine the ac-
tivities of several independent enzymes, and
thereby reflect the function of several different
genes. Attempts have been made in pharmaco-
genetics to follow the appearance of a drug metab-
olite, rather than simply the disappearance of the
parent compound; examples ofsuch work include a
twin study of the rate of production of the major
halothane metabolite (10) and a twin study on the
major metabolite of nortriptyline (11).
Family studies of drug elimination may be less
satisfactory than twin studies for two reasons, the
first being that the disposition ofcertain therapeutic
agents changes with age and varies according to
sex. Twin studies are by definition age-corrected,
but the results of family studies are difficult to in-
terpret because of the difficulty in correcting for
this poorly defined change in drug disposition with
age. Secondly, rates ofdrug metabolism have been
altered either in laboratory animals or in man by
such environmental constituents as caffeine,
nicotine, 3-methylcholanthrene, 3-4-benzpyrene,
and various insecticides. Therefore, the closer en-
vironmental similarity of children as compared to
parents could be partially responsible for changes in
drug-metabolizing capacity observed in family
studies. The influence exerted by numerous en-
vironmental constituents on drug-metabolizing
capacity may explain why, in one family study, a
correlation was found between healthy, nonmedi-
cated husbands and wives in their plasma half-lives
of phenylbutazone.
Environmental Factors and
Genetic Control of
Their Expression
The genetic control of large variations among
healthy, nonmedicated volunteers in rates of drug
elimination has several potentially useful implica-
tions. In the first place, since rates ofdrug elimina-
tion are genetically, rather than environmentally,
controlled in healthy, nonmedicated subjects, they
should be highly reproducible, stable values. This
expectation has been verified for several different
drugs.
Secondly, determination of drug-metabolizing
capacity in an individual might be ascertained be-
fore chronic drug administration as a guide to ad-
justing dosage according to individual require-
ments, thereby helping to reduce frequent
occurrences of toxicity or undertreatment encoun-
tered when the same dose of a drug is given to all
subjects. One method for measuring interindividual
differences in drug metabolism and for taking these
interindividual variations into account in selecting
an appropriate dose of drug is to ascertain drug
concentrations in biological fluids. Determination
of drug Mid metabolite concentrations in biological
fluids has assumed an important role in clinical
medicine. The question concerns what agents
should be closely monitored in the biological fluids
ofpatients. In general, the ideal compound for such
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Variations in response to xenobiotics caused by genetic factorsa
Species Response
Mouse Chloroform susceptibility
Hexobarbital sleeping time
Histamine sensitivity
High insulin tolerance
Phenothiazine protection against audiogenic seizures
Iproniazid lethality and hepatic injury
Ethanol preferences
d-Amphetamine lethality
Chlorpromazine sensitivity
Serotonin toxicity
Tumorigenesis
Aging and spontaneous cancers
Teratogenesis
Aryl hydrocarbon hydroxylase induction by polycyclic hydrocarbons
8-Aminolevulinic acid synthetase induction by 3,5'-dicarbethoxy-1,4-dihydro-2,4,6-trimethylpyridine (DDC)
2,3,7,8-Tetrachlorodibenzo-p-dioxin-produced teratogenesis
Skin ulcers caused by 7,12-dimethylbenz[a]anthracene
Cholesterol biosynthesis
NADPH-generating capacity
Induction of cytochrome P1450 by polycyclic hydrocarbons
Cadmium-induced testicular necrosis
3-Methylcholanthrene-initiated tumorigenesis
Induction of 7-ethoxycoumarin O-deethylase, p-nitroanisole O-demethylase, and 3-methyl-4-methylamino-
azobenzene N-demethylase activities by polycyclic aromatic compounds
Rat Thiourea toxicity
Trichlorobutanol stimulation of ascorbic acid and glucuronic acid excretion
Ethanol preference
Antipyrine metabolism
UDPG transferase deficiency (Gunn rat)
Serotonin toxicity
Morphine addiction
Sensitivity to warfarin
Aniline hydroxylation and ethylmorphine N-demethylation
Aldehyde dehydrogenase induction by phenobarbital
Cholesterol 7a-hydroxylase induction by phenobarbital
Serum esterases 1, 2 and 3
Serum esterases 4 and 5
Liver microsomal esterase
Susceptibility to ozone toxicity
Coumarin hydroxylase induced by phenobarbital
Zoxazolamine paralysis time
Phenacetin O-deethylase induction by polycyclic hydrocarbons
Acetylarylamine (2-acetylaminofluorene) N-hydroxylase induction by polycyclic hydrocarbons
Lung and aryl hydrocarbon hydroxylase induction by cigarette smoke
Acetaminophen-caused hepatic necrosis
Shortened survival time in mice exposed to polycyclic hydrocarbons, lindane and halogenated hydrocarbons
Induction of biphenyl-2-hydroxylase, biphenyl-4-hydroxylase and acetanilide hydroxylase activities and naph-
thalene-1,2,-dihydrodiol formation by polycyclic aromatic compounds
Reduced NAD(P):menadione oxidoreductase induction by polycyclic aromatic compounds
UDP glucuronyl transferase induction by polycyclic aromatic compounds
Rabbit Bishydroxycoumarin inactivation
Cocaine esterase
Lactogenic effect of reserpine
Atropine esterase
Metabolism of nine drugs before and after phenobarbital treatment
Slow and rapid isoniazid inactivation (N-acetyltransferase)
'Table from Nebert and Felton (1).
October 1977 167an approach is one possessing a low therapeutic
index but with clearly separable ineffective,
therapeutic and toxic regions ofdrug concentration
in biological fluids. The agent should be potent, act
reversibly at receptor sites, and exhibit large in-
terindividual variations in metabolism so that the
same dose could conceivably yield ineffective,
therapeutic and toxic blood concentrations in dif-
ferent subjects. Recently, Koch-Weser has sug-
gested that for digitoxin, digoxin, phenytoin,
lidocaine, lithium, nortriptyline, procainamide,
propranolol, quinidine, and salicylates, whose
therapeutic serum concentration he lists, determi-
nations of blood concentration yield significant in-
formation helpful to the physician in the manage-
ment of certain patients.
In experimental animals many pharmacogenetic
studies have been performed that reveal how the
action ofvarious drugs orchemicals can be affected
in different species by the particular genotype of
that species. Variations in response to zenobiotics
caused by genetic factors are listed in Table 4.
Over the past several years, interest has focused
on a wide variety ofenvironmental factors that can
affect rates of drug elimination in human subjects.
Because rates ofdrug elimination in human subjects
exhibit large interindividual variations and are in-
fluenced by so many different factors, studies de-
signed to identify specific factors must be carefully
controlled in order to exclude a host of variables
that could exert influence while selecting and quan-
titating only a single factor as an independent vari-
able. Without adequately controlling many of the
factors listed in Table 1, what appears initially to be
an effect ofa single factor could eventually prove to
be a product of many interacting or associated fac-
tors. The task of partitioning large interindividual
variations in drug elimination of exceedingly
heterogeneous populations into component parts is
complicated because some seemingly pure "en-
vironmental" factors such as smoking and diet are
closely associated with other environmental as well
as with genetic characteristics.
In 1969 a technique was introduced to overcome
this major difficulty of adequately controlling
human studies on factors that affect rates of drug
elimination (12). This approach depended on the
use of each subject as his own control (12). An-
tipyrine was measured in an apparently basal state.
Then a single condition in the volunteer's environ-
ment was changed, such as the institution of
chronic drug administration, and antipyrine phar-
macokinetic measurements were repeated during
and after the period ofchronic drug administration.
The quantitative differences between the phar-
macokinetic values obtained prior to and after
chronic drug administration or some other test con-
dition indicated to what extent the chronic drug
administration or the other test condition affected
hepatic antipyrine metabolism. Several precautions
and assumptions had to be taken. It was necessary
to determine the apparent volumes of distribution
(aVd) ofantipyrine in both the basal and perturbed
states since a change in aVd, rather than in hepatic
metabolism, could produce altered values for an-
tipyrine half-life or metabolic clearance rates. The
decay ofantipyrine in plasma had to be shown to be
proportional to the rate of production of the major
antipyrine metabolite, 4-OH antipyrine, if decay of
antipyrine in plasma was to be acceptable as a
measure of its metabolism. This relationship, sug-
gested in 1950 by the work of Brodie and Axelrod
(4) on the metabolic conversion in man ofantipyrine
to 4-OH antipyrine, has recently been confirmed in
other laboratories (13, 14). Figure 2 demonstrates
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Vesell et al. (14).
this relationship for antipyrine and Figure 3 reveals
that it applies as well for aminopyrine, another test
drug that is now being used (13-16). The existence
of a basal state of drug-metabolizing activity in a
test subject needed to be investigated. Otherwise,
each pharmacokinetic value obtained in a so-called
"normal" volunteer, rather than being truly basal, at
that time might represent a transient phase ofinduc-
tion or inhibition, depending on the individual's ex-
posure to conditions or compounds that can acceler-
ate or retard antipyrine elimination. Assurance that
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an individual is in a truly basal, uninduced or unin-
hibited, state can never be complete; it is partially
attainable through repeated measurements of the
rate ofelimination of a particular drug, and through
a careful history of exposures at work and at home
to compounds or conditions.
Table 5 provides a means of comparing the mag-
nitude of interindividual and intraindividual varia-
tions in drug distribution. The half-lives ofboth an-
tipyrine and bishydroxycoumarin are highly repro-
ducible in a given individual; interindividual varia-
tion is approximately 10 to 20% for each drug.
However, the range ofinterindividual variations for
bishydroxycoumarin extends over 1000% and for
antipyrine approximately 400%. Intraindividual
variations may be attributed to environmental fac-
tors that fluctuate in their temporal impact on an
individual; such fluctuating environmental factors
are of small consequence compared to large, genet-
ically controlled, interindividual variations in drug
disposition (Table 5).
Although a disease process may alter the phar-
macokinetic parameters of a given drug in an in-
dividual by only 20%o, this negligible change can be
clinically significant for a potent drug with a low
therapeutic index. Such small changes in rates of
drug elimination may require compensation by ap-
propriate alterations in dose.
Determination of plasma antipyrine half-lives as
aconvenient, simple test ofassessing rates forhepat-
ic antipyrine metabolism (17), and its further re-
finement permits each individual to serve as his
own control in investigating effects of drugs, en-
vironmental chemicals or other conditions on hepa-
tic antipyrine metabolism (12). With this test,
studies have been undertaken to measure the rela-
tive contributions of a number of different factors,
Table 5
Reproducibility of plasma half-lives of bishydroxycoumarin and antipyrine in normal volunteers
Plasma half-life, hr
Volunteer Drug Initial Repeat % Change
D.H. Bishydroxycoumarin 46.0 45.0 2.2
D.W. 44.0 42.5 3.4
Ge.L. 72.0 66.8 7.2
Gu.L. 69.0 70.8 2.6
Ja. T. 74.0 70.8 4.3
Jo.T. 72.0 73.6 2.2
Ja.H. 7.0 7.5 7.1
Je.H. 19.0 18.4 3.2
T.Ch. Antipyrine 10.6 11.3 6.6
T.C. 12.5 11.4 8.8
G.Z. 7.7 7.5 2.6
T.L. 12.7 13.2 3.9
R.F. 22.4 20.5 8.5
M.R. 13.1 13.3 1.5
C.H. 9.5 10.0 5.3
P.M. 5.8 6.0 3.5
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169 October 1977e.g., age, diet, cigarette smoking, etc., to large in-
terindividual variations in antipyrine metabolism.
While these studies can be useful in identifying
qualitatively diverse factors that can potentially
contribute to interindividual variations in drug dis-
position, pitfalls exist in quantitative interpretation
ofsuch data. For example, recent studies onfactors
contributing to large interindividual variations in
antipyrine metabolism and in theophylline disposi-
tion claim that age, cigarette smoking, diet, and an-
tifertility pills account for approximately half the
total interindividual variation in the disposition of
these drugs. Such conclusions are questionable for
several reasons. One reason is that the small sub-
population examined in each study could be unrep-
resentative of the entire population of the particu-
lar area with respect to the incidence of the factor
under examination. For example, the contribution
of diet to interindividual variations in antipyrine
metabolism was studied in a group receiving an-
tipyrine in which a relatively large percentage con-
sisted ofvegetarians. However, in the total popula-
tion of London, from which the study group was
drawn, the number of vegetarians is exceedingly
low, much less than 1%. It is erroneous to extrapo-
late to the whole London population the effect of
diet on antipyrine disposition in their specially
selected subpopulation. While in a population
where 50% of the subjects are vegetarians diet may
contribute significantly to large interindividual
variations in antipyrine metabolism, in another very
large population where there are no vegetarians,
absence of meat from the diet obviously cannot be
considered as contributory to the interindividual
variations observed. Thus, the principle must be
firmly established that quantitative extrapolation of
the influence ofa particular factor from one popula-
tion to another is valid only if the proportion of
individuals exposed to the particular factor is com-
parable in the two populations.
Another problem in studies of this type is en-
countered when different factors such as, for exam-
ple, smoking and diet are examined as independent
variables, regarded exclusively as "environmen-
tal." However, smoking and dietary habits are not
isolated traits, but rather are inextricably connected
with genetic and other environmental characteris-
tics. Smoking habits have been correlated with in-
tellectual, behavioral and genetic characteristics of
an individual; and smoking in high school students
is highly correlated with parental smoking habits
(18). Thus, rather than a simple single factor of ex-
posure to potent chemicals capable of inducing
drug-metabolizing enzymes, smoking should be
considered a complex trait closely associated with
other environmental conditions as well as with
genetic factors.
Effects of Age and
Circadian Rhythm
In most studies on drug disposition in normal
male subjects living under apparently basal condi-
tions the only limitations generally imposed on the
environment were that the volunteer should not
have consumed drugs for one month prior to the
study; this did not constitute a major change in their
habits, since they did not customarily receive
drugs. In these studies, however, the influence on
drug disposition of such variables as age, sex,
cigarette smoking, or consumption ofcoffee, tea, or
alcohol was not investigated. It has subsequently
become clear that age plays a small role in control-
ling the rate of elimination of certain drugs; an-
tipyrine half-life was 16.5% longer in older than in
younger subjects (19); a poor correlation existed be-
tween age and antipyrine half-life (r = -0.25) (19).
Although changes in rates of drug metabolism with
age are small compared with much larger interin-
dividual variations of sex and age in matched nor-
mal volunteers under basal conditions, the effect of
age alone on drug disposition depends on the par-
ticular drug under study. Thus, disposition of some
drugs such as aminopyrine exhibit greater change
with age than does antipyrine, whereas with others
such as ethanol it does notchange at all. Significant
alterations in drug disposition occur over very
much shorter periods, both circadian and seasonal
changes in rates of drug disposition having been
recorded. We observed that in some normal male
volunteers the half-lives of both phenacetin and
acetaminophen are approximately 15% shorter at
2:00 p.m. than at 6:00 a.m. (Fig. 4) (20).
Our own studies (21), as well as those of others
(22), revealed that chronic ethanol ingestion in-
creased the metabolism of drugs in some, but not
all, subjects. And cigarette smoking altered
phenacetin metabolism (23,24) and accelerated
antipyrine metabolism (25). On an isocaloric diet,
alterations of the carbohydrate to protein ratio
changed antipyrine and theophylline metabolism
(26). Low protein was associated with retarded
metabolism of these drugs (26). Nevertheless, in
obese subjects starvation for 7 to 10 days failed to
alter antipyrine or tolbutamide metabolism (27).
Occupational exposure to certain environmental
chemicals, such as DDT, accelerated metabolism
of phenylbutazone and cortisol (28), as well as of
antipyrine (29). Thus some environmental factors
affecting drug disposition in experimental animals
(Table 1) also operate in man.
If environmental agents were mainly responsible
for large variations in drug disposition among nor-
mal subjects, it would be anticipated that with in-
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the mean 6:00 a.m. value as control. Mean ± SD are indi-
cated above bars. Reproduced from Shively and Vesell (21).
creasing age there would be increasing rates ofdrug
metabolism. This supposition is based on the fact
that most environmentally encountered chemicals
such as DDT, PCB (polychlorinated biphenyls),
and polycyclic hydrocarbons are potent inducing
agents; thus, increasing exposure to these com-
pounds with time should be accompanied by accel-
erated drug metabolism with age. However, in-
terindividual variations in drug disposition cannot
be explained simply on the basis of increasing ex-
posure with time to potent inducing agents. Drug
metabolism has been found to be most active in the
pediatric age (30), less so in adulthood (19) and least
in old age (19). Clearly other factors must be in-
volved. One commonly encountered environmental
chemical, the birth control pill, inhibits hepatic drug
metabolism (31, 32), but age as a factor in the ob-
served decrease in rates of drug metabolism of this
chemical can be excluded for several reasons,
among them that the main age effects are observed
in the pediatric and geriatric groups and that de-
creased drug elimination occurs with age in groups
composed entirely of males.
Effects of Disease on
Drug Metabolism
Only recently was abnormal drug metabolism
demonstrated convincingly to accompany various
disease states. This association remained unproven
so long because of the contrasting problems of in-
vestigating disease states in laboratory animals and
human beings. In experimental animals the effect of
disease states on drug disposition can be carefully
measured because the environmental and genetic
characteristics can be determined and controlled
rigorously; several such disease states in which ap-
propriate studies on animals showed that drug dis-
position was altered are listed in Table 1. Develop-
ment of a highly reproducible model in the animal
permitted precise quantitation ofthe effects on drug
disposition produced by a specific pathologic lesion
ofknown intensity and severity, and made possible
a comparison with drug elimination under normal
basal conditions in the same animal.
By contrast, in human disease each patient rep-
resents an almost unique constellation of genetic
and environmental variables. Thus, variation in
drug disposition due to these factors is immense.
Furthermore, a very broad spectrum exists in the
severity, intensity, and duration ofmost human dis-
ease; large changes in the disease process and its
effects occur commonly with time, even when only
a single organ is affected. Generally, however, sev-
eral organs are simultaneously involved. The func-
tional status of the cardiovascular, endocrine,
hepatic, hormonal, and nervous systems fluctuates
during many disease processes that produce time
fluctuations in drug disposition. In addition, such
variables as age, sex, genetic constitution, diet,
weight, body size, exposure to other drugs, en-
vironmental chemicals, etc., differ among patients.
In addition to these complications, the normal rate
ofdrug elimination prior to disease is rarely known.
Thus, it is often impossible to determine whether
the rate of drug elimination measured in a given
patient constitutes a change from his normal basal
rate.
Many different disorders and pathologic states
can alter the normal rates and pathways for drug
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171absorption, distribution, biotransformation, excre-
tion, interaction with receptor sites or various com-
binations of these. Since each drug has a distinct
profile for these five processes, the extent to which
a disease that affects these processes will alter the
distribution of a drug depends on the particular
drug. Therefore, it is hazardous to extrapolate how
pathologic processes will affect other drugs on the
basis ofpathologic effects that alter the distribution
of the one drug. Furthermore, the clinical conse-
quences of a change in drug distribution produced
by disease will be determined also by the therapeu-
tic index of the drug as well as by certain genetic
and environmental characteristics of the patient.
For example, a change of 200% in the plasma half-
life ofantipyrine, salicylates, or penicillin will prob-
ably have little or no clinical consequence, whereas
a change of 20% in the plasma half-life of digoxin,
procainamide, or lidocaine may prove critical. By
the same token, a change of 1% in the albumin bind-
ing ofwarfarin, which normally is 99% bound, may
have profound toxicologic results, whereas a
change of 1% in the albumin binding ofprobenecid,
which normally is 75% bound, has negligible clinical
consequences. Here the crucial factor is the percent
change in the free, but not bound, portion of the
drug.
Effects ofdisease states on the rate ofabsorption
of the drug depend on many factors including the
site of drug administration. If the drug is adminis-
tered orally, the influence of disease on rates of
drug absorption will depend on the nature of the
disease process, whether it affects the areas in the
gut where the drug is normally absorbed, how the
disease alters the normal physiologic volume, pH,
temperature, viscosity, surface tension and com-
position of the gastrointestinal secretions and con-
tents (33). Rates of drug absorption may also be
influenced by whether or not food is present, the
nature and quantity ofbile salts and bacterial flora,
the rate of splanchnic blood flow, prior diet and
food intake as well as gastrointestinal motility (33).
Until recently little was known about how disease
states altered these factors in man; however, large
interindividual differences in rates of absorption of
many orally administered drugs occur in hospital
patients (34-36) as well as in normal volunteers
(37-39). For example, a 7-fold range in the amount
of tetracycline absorbed was reported in six fast-
ing, healthy subjects (40). Variations ingastric emp-
tying may contribute significantly to large interin-
dividual differences in drug absorption rate because
numerous physiologic conditions, such as posture
and autonomic activity, as well as the temperature,
volume, viscosity and tonicity of gastric contents,
can change gastric emptying time. Grossly impaired
absorption of paracetamol occurs in patients with
delayed gastric emptying and pyloric stenosis (41).
In patients with slow gastric emptying L-dopa may
be ineffective (42). Therapeutic failure of orally
administered drugs usually accompanies gastric
stasis (41,43,44). In patients with achlorhydria, as-
pirin was absorbed significantly faster, and plasma
salicylate concentrations were higher than in con-
trols (Fig. 5) (44). Prescott (45) reported the in-
teresting observation that acetaminophen plasma
concentrations were significantly higher after oral
administration in 12 convalescent hospital patients
in bed than in seven healthy ambulant volunteers
matched for age and sex.
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FIGURE 5. Mean plasma salicylate concentrations in achlorhy-
dric and control patients following an oral dose of 900 mg of
acetylsalicylic acid. Reproduced from Prescott (45).
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172Since rates of absorption of orally administered
pills and capsules are dependent on rates of their
dissolution and dispersion, some of the factors
enumerated above can alter such rates, thereby
contributing to variations in drug absorption. It is
interesting and somewhat surprising that the ab-
sorption ofp-aminosalicylic acid and insoniazid was
unchanged by gastrectomy performed for peptic
ulcer, although complete failure ofethionamide ab-
sorption occurred in some patients (46). Further-
more, gastrectomy failed to alter the absorption of
sulfisoxazole, quinidine or ethambutol unless
vagotomy had been performed, thereby slowing gas-
tric emptying (47).
In jejunal disease folic acid absorption is di-
minished (48). In ileal disease the transport of bile
acids may be impaired, as well as the enterohepatic
transport of many lipid soluble drugs, since bile
acids promote the gastrointestinal absorption offat
and certain fat soluble compounds including many
drugs and vitamins A, D, K, and E. Ileal disease
may be associated with impaired B12 absorption,
since B12 is absorbed in the ileum after it forms a
complex with intrinsic factor produced by the gas-
tric parietal cell. Defective function of the ileum
secondary to surgical removal or disease through
interference with B12 absorption can lead to per-
nicious anemia. B12 absorption can also be impaired
in gastric diseases where parietal cell function is
abnormal, producing intrinsic factor deficiency and
pernicious anemia. In some patients with pernici-
ous anemia precipitating or blocking antibodies to
intrinsic factor have been identified (49, 50). In ad-
dition, regional enteritis as well as tropical sprue,
celiac disease, and Whipple's disease can produce
B12 malabsorption. In steatorrhea, fat-soluble drugs
and vitamins may be lost in the feces, producing
deficiency of the fat-soluble vitamins, a deficiency
of vitamin D being by far the most significant
chronic problem in gastrointestinal disease.
Some active drugs are produced after metabolism
ofthe inactive form by gut bacteria, the best exam-
ple being cleavage of salicylazosulfapyridine, the
drug ofchoice in the treatment ofchronic ulcerative
colitis. Diseases or drugs that change the nature of
the gastrointestinal flora can affect the disposition
ofotherdrugs metabolized by gut bacteria. Possibly
the effect oflarge doses of charcoal on gastrointes-
tinal absorption of phenacetin is mediated by gut
bacteria and induction of AHH activity in these
bacteria by charcoal (51). The absorption ofdigoxin
is reduced by neomycin administration (52).
The binding of many drugs to albumin is altered
in several disease states. For example, the pheny-
toin binding was decreased in plasma of 15 uremic
patients (53). The size of the unbound fraction cor-
related well with blood urea nitrogen, serum
creatinine and clinical state of the patient. In addi-
tion to phenytoin, other organic acids including
congo red, sulfonamides, thyroxine, tryptophan,
clofibrate, fluorescein, and methyl red exhibited
decreased protein binding in uremia. By contrast,
most organic bases bind normally to plasma from
uremic patients. A clinically significant neutral
compound, digitoxin, exhibited decreased plasma
binding in uremic patients (54). Disease states in-
cluding cirrhosis and nephritis are associated with
hypoproteinemia and hypoalbuminemia. In both
these conditions the unbound fraction ofmost drugs
is elevated compared to the unbound fraction that
exists with normal protein and albumin concentra-
tions. These situations illustrate the danger of
selecting drug dose solely on the basis oftotal drug
concentrations in plasma, rather than on the free
concentration, since only the free form is phar-
macologically active. In cirrhosis, the plasma bind-
ing of the organic bases quinidine, diazepam and
triamterene, as well as of the organic acid fluores-
cein are all decreased.
Since poor renal function is associated with de-
creased excretion ofseveral drugs, it is important to
modify normal drug dosage in uremic patients.
Methods for this have been presented by Dettli and
others (55-58). Dettli (57) described a linear rela-
tionship between the overall elimination rate con-
stant ke and the endogenous creatinine clearance
(Vcr'):
ke = knr + 8Vcr'
where knr is the mean extrarenal elimination rate
constant in anuric patients and 8 is a constant relat-
ing Ver' to the renal elimination rate constant kr of
the drug. This equation can be used for about 40
drugs; simple nomograms have been devised which
allow the estimation of the rate of drug elimination
in the patient with kidney disease from the value of
Vcr' (57, 59). However, there are numerous drugs
whose apparent elimination rates are unaltered by
uremia, including tolbutamide, phenobarbital, his-
tamine, phenacetin, phenytoin, antipyrine, quin-
idine, propranolol, and vitamin D (53).
Much less study has been devoted to effects of
disease states on receptor sites and the kinetics of
formation and dissociation of drug receptor com-
plexes. Comparison of the basal state of receptors
under normal and disease conditions should facili-
tate analysis of drug action. Advances in receptor
isolation by techniques such as affinity labeling now
permit careful in vitro studies to assess how dis-
eases affect receptors. For example, such tech-
niques have the potential of revealing whether
cholinergic receptors from mysasthenic skeletal
October 1977 173muscle function normally in response to transmitter
and in the kinetics ofdrug binding and dissociation.
Diseases can also alter the local environment of
receptors and change their conformation. A classic
example of how environmental conditions alter the
binding of a drug to its receptor is that of digoxin
with receptors in cardiac muscle, where the efficacy
ofthe drug in producing inotropic and chronotropic
effects can be appreciably altered by changes in
potassium ion concentration or pH near the recep-
tor.
Effect of Fever on
Drug Disposition
In the course of many diseases, fever, a con-
comitant of many diseases, develops either acutely
or chronically. Yet, until recently, the effects of
fever on drug distribution were unexamined. In
1975, it was shown that etiocholanolone-induced
fever in normal volunteers was associated with the
prolongation of plasma antipyrine half-life in 11 of
14 volunteers who developed fever (60) (Fig. 6).
These results have been confirmed by Trenholme
et al. (61), who demonstrated retardation ofquinine
elimination both in etiocholanolone-induced fever
and in fever associated with experimentally induced
malaria. The effects of drug distribution need to be
studied both with more drugs and in other febrile
states before generalizations concerning the role of
fever in drug disposition and appropriate dosage
compensation can be made.
Effect of Thyroid Disease on
Drug Disposition
An extensive literature based on experimental
animals describes various effects produced by al-
tered thyroid function on drug disposition. In 1973,
patients with hyperthyroidism were shown to ex-
hibit accelerated antipyrine metabolism, whereas
patients with hypothyroidism displayed prolonga-
tion of plasma antipyrine half-life (62) (Fig. 7).
These observations were confirmed in 1974 (63) and
were extended in 1975 (64) (Fig. 8) to other drugs.
Thus, for drugs of low therapeutic index that are
metabolized by the hepatic mixed function oxi-
dases, the appropriate dose can be significantly al-
tered by the functional status of the thyroid.
Studies on Drug Distribution in
Patients with Liver Disease
For many years uncertainty prevailed concerning
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FIGURE 6. Plasma antipyrine half-life after an oral dose of 10
mg/kg antipyrine in aqueous solution given to normal volun-
teers in an afebrile state (o) and again during production of
fever by etiocholanolone administration (.). Note prolonga-
tion of plasma antipyrine half-life by fever in most, but not
all, volunteers. Data from Elin et al. (61).
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the relationship between liver disease and drug
metabolism. Levi, et al. (65) in 1968 revealed that
hrs. this ambiguity arose in part from failure to consider
how concomitantly administered drugs affected the
metabolism ofthe drug under stildy. In 1971 Cooks-
ley and Powell (66) showed that the metabolic
pathway for the hepatic biotransformation of pred-
nisone was affected by liver disease and that the
extent of this effect depended on the nature and
severity ofthe disease. In 1972 Faigle (67) reported
that in patients with severe bilharziasis, metabolism
ofthe schistosomacide niridazole (nitrothiamidazol)
was impaired, as revealed by higher blood levels of
the drug and a higher incidence of adverse effects
than in normal subjects. In 1973 Branch et al. (68)
reported that serum antipyrine half-life was pro-
longed in patients with liverdisease, an observation
confirmed in 1974 by Andreasen et al. (69) and by
Andreasen and Vesell (70) (Fig. 9). Also in 1974,
hrs. Hepner and Vesell (15) reported that aminopyrine
metabolism was deranged in a large percentage of
QN, patients with liver disease and proposed an
QN, aminopyrine breath test (ABT), in which 14CO2 was
L.. measured in breath after the administration of
4-dimethyl-14C-aminoantipyrine (14C-aminopyrine),
as a sensitive, clinically convenient test of hepatic
function and drug metabolism. The virtue of this
method was that it measured production of a
metabolite, rather than disappearance of the parent
hrs. drug. It is now abundantly clear from numerous
studies that the rate of disappearance of cold
aminopyrine or antipyrine in plasma of a patient
correlates highly with the rate ofproduction oftheir
major metabolites (14).
Further studies utilizing patients with various
hepatic disorders disclosed that the ABT differen-
tiated different types of hepatic dysfunction (71)
(Fig. 10). For example, in 16 of 21 subjects with
cholestasis not caused by malignant disease, the
mean 14CO2 excretion was normal. The mean per-
centage of administered 14C excreted in 14CO2 in 2
hr in control patients was 7.1 + 1.3 (SD)% and
significantly less (p < 0.01) in patients with portal
cirrhosis (2.6 ± 1.2%), fatty liver (4.7 + 1.1%),
hepatitis (2.6 ± 1.4%), and hepatic malignancy (3.5
+ 1.8%) (71) (Fig. 10).
It is now firmly established that hepatocellular
disease is associated with decreased capacity to
metabolize some drugs. However, it has not yet
been determined whether the extent of depression
of hepatic drug-metabolizing function in an indi-
vidual with liver disease is similar for all drugs bio-
transformed by the liver.
Our observations that rates of aminopyrine
elimination are reduced in almost all patients with
parenchymal liver disease and observations by
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FIGURE 7. Prolonged antipyrine half-lives in two hypothyroid
patients and shortened antipyrine half-lives in two hyper-
thyroid patients relative to the normal antipyrine half-lives in
36 healthy volunteers of 10.9 + 0.5 hours. Reproduced from
Vesell and Passananti (63).
Branch (68) and Andreasen (69, 70) that liver dis-
ease is also accompanied by reduction in rates of
hepatic antipyrine metabolism can be harmonized
with observations of Williams et al. (72) and that
warfarin disposition during acute viral hepatitis is
unchanged and of Shull et al. (73) that oxazepam
disposition is normal during acute viral hepatitis
and cirrhosis. Between these extremes, a group of
drugs of which clindamycin is an example appar-
ently produce intermediate or moderate changes in
disposition in liver disease (74). A wide range, from
no change whatever in disposition to significant re-
tardation, has been reported in liver disease, de-
pending on the drug studied. For drugs with high
hepatic extraction ratios, greater than 0.8, such as
propranolol and lidocaine, alterations in blood flow
accompanying liver disease can produce large
changes in hepatic clearance of the compound. For
drugs with very low hepatic extraction ratios, less
than 0.2, such as antipyrine and aminopyrine, large
variations in the extent to which hepatocellular dis-
ease alters their rates of metabolism cannot be due
to abnormal liver blood flow. They may be attrib-
uted in part to multiple molecular forms of hepatic
FIGURE 8. Values for plasma antipyrine half-life in normal sub-
jects and in patients with hyperthyroidism and hypo-
thyroidism. Each closed circle represents the value for a
single individual. Reproduced from Vesell et al. (65).
cytochrome P-450 and to the differential effects that
a particular hepatic disorder might exert on these
forms.
Heterogeneous effects of liver disease on drug
disposition are in accord with previous studies in
normal individuals that established lack of correla-
tion in rates of hepatic biotransformation of differ-
ent drugs. In normal individuals rates of hepatic
biotransformation of antipyrine did not correlate
with rates of hepatic biotransformation of such
other drugs as phenylbutazone and bishydroxy-
coumarin (75), an observation confirmed by Kadar
et al. (76). No inherent incompatibility exists be-
tween failure to correlate rates ofdrug metabolism in
the basal state and high correlation of these rates
when the hepatic drug-metabolizing system is in-
duced or inhibited. One explanation for this is the
heterogeneity, both qualitative and quantitative, of
cytochrome P-450, each ofthe multiple forms prob-
ably acting on different drug substrates (77). When
an inducing or inhibiting compound is administered,
one (or a few) of these forms is selectively altered.
Consequently, a greater uniformity of response oc-
curs in different subjects as identified by adminis-
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rate of antipyrine metabolism was produced by
phenobarbital for all subjects in the study, even
though in some it changed more than in others to
attain this rate (12). These observations are compat-
ible with and help explain lack ofsignificant correla-
tions among rates of elimination of some drugs in
the basal, unmedicated state, but significant corre-
lation in the induced state of drug metabolism.
CONTROLS CIRRHOSIS FATTY HEPATITIS CANCER CHOLESTASIS
LIVER
I[ I I1
0 3 6 9 1 2 15 18 21 24 FIGURE 10. Percentage ofadministered 'IC excreted as '4CO2 in
HOU R S A F T E R A N T I P Y R I N E
breath 2 hours after oral administration of [14C]aminopyrine.
Transverse lines represent mean
± SEM; hatched areas rep-
resent SD. Reproduced from Hepner and Vesell (72).
FIGURE 9. Decay of antipyrine after oral and intravenous ad-
ministration to three patients with cirrhosis of the liver. The
oral and intravenous doses were separted by an interval of 8
days. Reproduced from Andreasen and Vesell (71).
tration of a test drug if that drug is the substrate for
the particular cytochrome P-450 that has been al-
tered. Although large interindividual variations in
the extent of induction as measured by percent
change in plasma antipyrine half-life from the basal
level have been reported (12), an inducing agent
such as phenobarbital reduced interindividual varia-
tions in antipyrine elimination rates measured in
unmedicated, normal volunteers. A more uniform
Methodologic Problems
Predictive Values of Correlation
Coefficients Between Rates of Elimination
of Different Drugs in the Same Subject
A discussion ofthe biologic significance of corre-
lations among pharmacokinetic values of several
drugs determined within the same normal volunteer
seems warranted because of the current popularity
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177of such correlations and the misconceptions con-
cerning their clinical applicability. The principal
aim of such correlations among rates ofelimination
ofdifferent drugs in the same subject is to predict in
a given patient the behavior of one drug as against
another. The predictive value is not equivalent to
the correlation coefficient, as implied in so many
recent studies, but rather to the square ofthe corre-
lation coefficient. In clinical practice, the useful-
ness ofpredictive values ofless than 90% is limited;
to achieve apredictive value of90%, the correlation
coefficient must be 0.95. With lower correlation
coefficients, the difference between the predictive
value and the correlation coefficient is larger. For
example, a correlation coefficient of0.80 has a pre-
dictive value of0.64; and acorrelation coefficient of
0.60 has a predictive value of0.36, so that in only 1
of 3 patients would a prediction based on such a
relationship be accurate. It must be stressed that a
low p value does not necessarily indicate that the
correlation is biologically significant or clinically
useful. Thep value does not provide information on
the biologic significance ofarelationship, but rather
on the probability of reproducing the best line that
can be drawn through as many ofthe data points as
possible. Thus, a correlation coefficient of 0.30 or
0.60 or even 0.80 may have a p value of0.001, but
the relationship between the rates ofelimination of
the drugs is too poor for practical clinical applica-
tion, since even the correlation coefficient of 0.80
yields a correct prediction in only 2 of 3 patients.
Furthermore, studies on small numbers of subjects
may yield a very high correlation between the
elimination rates of several drugs; such relation-
ships should be rechecked with larger groups, since
some high correlations obtained with small numbers
of volunteers have not been reproducible, even in
the same laboratory (78). Present data suggest that
the extent to which hepatic dysfunction alters rates
of elimination of exogenous compounds removed
by the liver varies according to the substrate.
Therefore, when patients with hepatic dysfunction
receive drugs eliminated through hepatic
mechanisms, the rate of elimination of one drug
may not be accurately extrapolated from phar-
macokinetic information concerning another; future
work may reveal discrete categories ofdrugs so that
how one drug in a category is eliminated in apatient
with liver disease will accurately enable extrapola-
tion to other drugs in the same category. In princi-
ple, however, the results in patients with liver dis-
ease agree with observations in normal, uninduced
volunteers (79), where one test drug does not satis-
factorily provide information concerning the dispo-
sition of others.
Hazards of Genetic Analysis
Based on Distribution Curves
Finally, there are limitations and pitfalls inherent
in interpreting distribution curves ofdrug response.
Itis becoming increasingly popular to construct dis-
tribution curves to investigate the quantitative vari-
ations in the elimination rate of or response to the
same dose ofadrug administered by the same route
to a group of unrelated normal subjects. Such
curves appear with increasing frequency in the lit-
erature, since this approach apparently permits
some degree of genetic analysis in groups of nor-
mal, unrelated volunteers, despite extreme genetic
and environmental heterogeneity with respect to
the factors (Table 1) that can affect drug elimination
and response. A bimodal or trimodal distribution
curve obtained in such groups is generally inter-
preted to indicate that interindividual variations in
drug elimination or response are caused by genes at
a single locus (monogenic control), whereas a uni-
model distribution curve suggests control by ge-nes
located at multiple loci (polygenic control). It must
be emphasized that by itself the shape of the dis-
tribution curve cannot prove or disprove a genetic
hypothesis: the only acceptable method of estab-
lishing the mode ofinheritance ofa trait in man is to
study its transmission in families. Distribution
curves can be helpful as clues on which to base
family studies, but can be misleading when relied on
without family studies. For example, unimodal or
multimodal distribution curves can arise entirely
from environmentally controlled factors or can be
generated by variations controlled entirely by genes
located either at multiple loci or at a single locus.
Thus, distribution curves as currently used in
pharmacogenetics cannot differentiate among these
alternatives. Moreover, it is often impossible to de-
termine the precise shape ofa distribution curve for
a small number of subjects. Discontinuity in the
distribution curve for unmetabolized isoniazid in
the 24 hr urine collected from ten sets of twins is
demonstrated in Figure 11. Trimodality was later
firmly established by appropriate family studies that
demonstrated autosomal recessive inheritance of
interindividual differences in the rates of isoniazid
acetylation. However, the distribution curves for
antipyrine and nortriptyline are less clear from the
few individuals shown in Figure 11. While the dis-
tribution ofantipyrine half-lives in the plasma of 14
sets of twins could be compatible with trimodality,
the distribution might also be unimodal. Studies on
larger numbers of subjects in several different
laboratories yielded a unimodal distribution curve
for antipyrine half-lives or metabolic clearance
Environmental HealthPerspectives 1785 10 15 20 25 30 35 40
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FIGURE 11. Distribution curves of response in three twin studies. Although the distribution is clearly multimodal for 24
hour excretion of isoniazid, the distribution of antipyrine half-lives in plasma and for steady state blood levels of
nortriptyline is less clear cut, the curves being compatible either with a unimodal or polymodal interpretation.
rates.
Plotting distribution curves based on phar-
macokinetic data may not accurately reflect rates of
drug metabolism, since many diverse factors influ-
enced by various genetic as well as environmental
characteristics affect such pharmacokinetic
parameters as the plasma half-life or even the
metabolic clearance rate of a drug. Thus, for many
drugs, distribution curves utilizing purely phar-
macokinetic data can be misleading because genetic
interpretations of these distribution curves suggest
that the trait being measured is much closer than it
actually is to a single gene product. This limitation
applies as well to family studies.
Future Needs and Directions
of Inquiry
This review of the present state of knowledge
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179concerning the role played by certain key variables
in determining how humans respond to environ-
mental chemicals and drugs has identified several
future needs and directions of inquiry.
In order to define the impact of various poten-
tially toxic chemicals in the environment on human
populations, it is necessary to estimate more accu-
rately the specific concentrations of various toxic
chemicals in different geographical areas and under
different working conditions, as well as to deter-
mine whether such potentially toxic compounds ac-
tually are present in human biological fluids and
tissues.
The normal mechanisms by which these toxic
compounds are handled must be better defined in
man and here, too, the need for better knowledge of
how to extrapolate from animal studies to man is
obvious.
Improvements in methodology are required at
various levels: (a) The further development of
chemical analytical methods and kinetic techniques
for the recognition oftrace amounts ofchemicals as
well as for the development of substitute surrogate
or model compounds where it would be unethical to
study highly toxic compounds in man; (b) the appli-
cation ofmore refined genetic analyses to polygenic
systems; (c) the development ofmethcds to identify
the discrete components of polygenic systems by
laboratory techniques; (d) the use of in vitro tech-
niques (including tissue culture) to predict the re-
sponse of individuals to drugs or compounds in the
environment.
The study of population genetics in order to: (a)
identify particular populations at high risk because
of their possession of certain alleles in high fre-
quency and (b) to elucidate ethnic variability in the
metabolism of or response to drugs and toxic com-
pounds.
The pathophysiological mechanisms underlying
proven associations between polymorphism and
disease, especially those produced or enhanced by
drugs, must be elucidated.
Genetic factors should be looked for when at-
tempts are made to unravel the mechanisms ofclin-
ically significant drug interactions.
It is critical to develop adequate animal models to
study the problems of human exposure to toxic
chemicals. We need to define better how far we can
safely extrapolate data from laboratory animals to
man if laboratory animals are to serve as satisfac-
tory models for the issues we are addressing.
In searching for genetic factors that cause in-
terindividual differences in response to environ-
mental chemicals and drugs, there is a need to
measure rates of production of the major metab-
olites of a toxic compound or drug, rather than the
rate of disappearance of the parent chemical.
This work was supported in part by grant CA-16536 from the
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